Investors
| # | Title | Year | Action |
|---|---|---|---|
| 1 | ANNUAL REPORT 2024-25 | 2024-25 | View |
| # | Title | Year | Action |
|---|---|---|---|
| 1 | Investor Meet Intimation-11-03-2026 | 2025-26 | View |
| 2 | Investor Meet Intimation-02-12-2025 | 2025-26 | View |
| 3 | Investor Meet Intimation-01-12-2025 | 2025-26 | View |
| 4 | Investor Meet Intimation-16-12-2025 | 2025-26 | View |
| 5 | Investor Meet Intimation-25-02-2026 | 2025-26 | View |
| 6 | Investor Meet Intimation-24-08-2025 | 2025-26 | View |
| 7 | Investor Meet Intimation-22-09-2025 | 2025-26 | View |
| 8 | Investor Meet Intimation-03-10-2025 | 2025-26 | View |
| 9 | Investor Meet Intimation-29-11-2025 | 2025-26 | View |
| # | Title | Year | Action |
|---|---|---|---|
| 1 | Outcome of Investors’ Meeting-11-03-2026 | 2025-26 | View |
| 2 | Outcome of investor meet -29-11-2025 | 2025-26 | View |
| 3 | Outcome of Investors’ Meeting-03-10-2025 | 2025-26 | View |
| 4 | Outcome of Investors’ Meeting-22-09-2025 | 2025-26 | View |
| 5 | Outcome of Investors’ Meeting-23-09-2025 | 2025-26 | View |
| 6 | Outcome of Investors’ Meeting-02-12-2025 | 2025-26 | View |
| 7 | Outcome of Investors’ Meeting-01-12-2025 | 2025-26 | View |
| 8 | Outcome of Investors’ Meeting-16-12-2025 | 2025-26 | View |
| 9 | Outcome of Investors’ Meeting-25-02-2026 | 2025-26 | View |
| # | Title | Year | Action |
|---|---|---|---|
| 1 | Certificate Deviation Report-31-03-2025 | 2024-25 | View |
| 2 | Structured Digital Database (SDD) Compliance Certificate- 30-06-2025 | 2025-26 | View |
| 3 | Structured Digital Database (SDD) Compliance Certificate- 31-03-2025 | 2024-25 | View |
| 4 | Change in CIN (Post Listing) | 2025-26 | View |
| 5 | Financials- Press Release-31-03-2025 | 2024-25 | View |
| 6 | Integrated Corporate Governance Report for the Quarter Ended December 31, 2025 | 2025-26 | View |
| 7 | Corporate Governance Report (Q3) - Integrated Governance-31-12-2025 | 2025-26 | View |
| 8 | Statement of Investor Complaints for the Quarter ended 31st March, 2025 | 2024-25 | View |
| 9 | NSE Disclosure-25-09-25 Regulation 7(2) | 2025-26 | View |
| 10 | Reconciliation of Share Capital-30-06-2025 | 2025-26 | View |
| 11 | Certificate under Regulation 7(3) of the SEBI (LODR) Regulations, 2015 | 2025-26 | View |
| 12 | Non-Applicability of Regulation 27(2) of SEBI (LODR) Regulation, 2015 | View | |
| 13 | Regulation 29 Prior intimation BM Approval of accounts 31-03-2025 | 2024-25 | View |
| 14 | Certificate as per Regulation 40(9) and (10) of the SEBI (LODR) Regulations, 2015 ("Listing Regulations") for the F.Y. ended on March 31, 2025 | 2024-25 | View |
| 15 | Regulation 76 -Reconciliation of Share Capital 31-03-2025 | 2024-25 | View |
| 16 | RTA Details | View | |
| 17 | Declaration under Regulation 31(4) read with Regulation 31(5) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. | 2024-25 | View |
| 18 | Structured Digital Database (SDD) Compliance Certificate SEBI (PIT) Regulations, 2015 for the quarter ended September 30, 2025 | 2025-26 | View |
| 19 | SHP- 31-12-2025 | 2025-26 | View |
| 20 | SHP- 31-03-2025 | 2024-25 | View |
| 21 | Statement of Deviation 31-03-2025 | 2025-26 | View |
| 22 | Declaration under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. | 2025-26 | View |
| # | Title | Year | Action |
|---|---|---|---|
| 1 | CODE OF BUSINESS CONDUCT AND ETHICS | View |
| # | Title | Year | Action |
|---|---|---|---|
| 1 | Insider Trading Policy | View |
| # | Title | Year | Action |
|---|---|---|---|
| 1 | Archival Policy | View | |
| 2 | Board Diversity Policy | View | |
| 3 | Insider Trading Policy | View | |
| 4 | Code of Conduct | View | |
| 5 | UPSI Policy | View | |
| 6 | Corporate Governance | View | |
| 7 | Criteria / Policy of Making Payments to Non-Executive Directors | View | |
| 8 | CSR Policy | View | |
| 9 | Familiarisation Programme | View | |
| 10 | Materiality Policy | View | |
| 11 | Nomination and Remuneration Policy | View | |
| 12 | Policy And Procedure for Inquiry in Case of Leak or Suspected | View | |
| 13 | Related Party Transaction Policy | View | |
| 14 | Policy on Preservation of Documents | View | |
| 15 | Policy on Sexual Harassment | View | |
| 16 | Policy on Material events | View | |
| 17 | Risk Assessment and Management Policy | View | |
| 18 | Terms and conditions of Appointement of I D | View | |
| 19 | Vigil Mechanism & Whistle Blower Policy | View | |
| 20 | Vigil Mechanism & Whistle Blower Policy | View | |
| 21 | POLICY ON MATERIAL SUBSIDIARIES | View | |
| 22 | Dividend Distribution Policy | View |
| # | Title | Year | Action |
|---|---|---|---|
| 1 | Financial Statements- Chandan Diagnostic Limited | 2021-22 | View |
| 2 | Financial Statements- Chandan Pharmacy Limited | 2022-23 | View |
| 3 | Financial Statements- Chandan Diagnostic Limited | 2023-24 | View |
| 4 | Financial Statements- Chandan Diagnostic Limited | 2024-25 | View |
| 5 | Financial Statements- Indra Diagnostic Centre & Blood Bank Limited | 2021-22 | View |
| 6 | Financial Statements- Indra Diagnostic Centre & Blood Bank Limited | 2022-23 | View |
| 7 | Financial Statements- Indra Diagnostic Centre & Blood Bank Limited | 2023-24 | View |
| 8 | Financial Statements- Indra Diagnostic Centre & Blood Bank Limited | 2024-25 | View |
| # | Title | Year | Action |
|---|---|---|---|
| 1 | List of Subsidiaries of Chandan Healthcare Limited | View |
| # | Title | Year | Action |
|---|---|---|---|
| 1 | Opening of a Diagnostic Centre in Ashiyana, Lucknow | 2025-26 | View |
| 2 | Opening of a Diagnostic Centre in Bhopal Madhya Pradesh | 2025-26 | View |
| 3 | Commencement of diagnostic operations in Kurukshetra, Haryana | 2025-26 | View |
| 4 | Commencement of Diagnostic Operations Kolkata | 2025-26 | View |
| 5 | Commencement of Diagnostic Operations in Mumbai | 2025-26 | View |
| 6 | Commencement of Diagnostic Operations in Kota, Rajasthan | 2025-26 | View |
| 7 | CRISIL Credit Rating-10-05-2025 | 2025-26 | View |
| 8 | Acquiring of X Life Diagnostics and Research Centre, Patna | 2024-25 | View |
| 9 | Investor Presentation-21-8-2025 | 2025-26 | View |
| 10 | Launch of Diagnostic Centre in Raipur Chhattisgarh | 2025-26 | View |
| 11 | Launch of Chandan Medical Centres | 2025-26 | View |
| 12 | Commencement of Diagnostic Operations at Mumbai, Maharashtra | 2025-26 | View |
| 13 | Opening of new Diagnostic Centre at Ayodhya, Uttar Pradesh | 2025-26 | View |
| 14 | Outcome of Investor Meeting held on October 3, 2025 | 2025-26 | View |
| 15 | Strategic Partnership with Jeena Sikho Lifecare Limited | 2025-26 | View |
| 16 | opening of new Diagnostic Centre at Prashant Vihar, New Delhi | 2025-26 | View |
| 17 | Commencement of diagnostic operations at Dera Bassi, Chandigarh, Punjab | 2025-26 | View |
| 18 | Submission of Earnings Release for the Quarter and Nine Months ended December 31, 2025 | 2025-26 | View |
| 19 | Investor Meeting-24-08-2025 | 2025-26 | View |
| 20 | Receipt of Award-Zee Dare to Dream | 2025-26 | View |
| 21 | Regulation 30-Schedule of meet - 22-09-2025 | 2025-26 | View |
| 22 | Schedule of meet 03-10-2025 | 2025-26 | View |
| 23 | Schedule of meet-17-09-2025 | 2025-26 | View |
| 24 | Revision-Award of PPP in Assam & Punjab | 2025-26 | View |
| 25 | Schedule of Post Earnings Conference Call for analysts and investors for H1 FY26 financial results | 2025-26 | View |
| 26 | Outcome of Board Meeting-27.03.2025 | 2024-25 | View |
| 27 | 10-year PPP project by the Punjab Health Systems Corporation-02-03-2026 | 2025-26 | View |
| 28 | Tender for installation of a 1.5 Tesla MRI system at Civil Hospital, Rohtak (Haryana)-24-03-2026 | 2025-26 | View |
| 29 | Outcome of Board Meeting-Loan from Axis Bank-31-12-2025 | 2025-26 | View |
| 30 | Award of Public Private Partnership (PPP) Project in Punjab-13-12-2025 | 2025-26 | View |
| # | Title | Year | Action |
|---|---|---|---|
| 1 | Article of Association | View | |
| 2 | Memorandum of Association | View | |
| 3 | Management Team Information | View | |
| 4 | Certificate of Incorporation | 2003-04 | View |
| 5 | Certificate of Registration of Regional Director order for Change of State | 2016-17 | View |
| 6 | Certificate of Registration of Regional Director order for Change of State | 2023-24 | View |
| 7 | Certificate of Registration of Regional Director order for Change of State | 2023-24 | View |
| 8 | Certificate of Registration of Regional Director order for Change of State | 2023-24 | View |
| 9 | Constitution of Committees | View | |
| 10 | Director's Profile | View |
| # | Title | Year | Action |
|---|---|---|---|
| 1 | Article of Association | View | |
| 2 | Red Herring Prospectus | View | |
| 3 | Draft Red Herring Prospectus | View | |
| 4 | List of Material Creditors | View | |
| 5 | NSE In-principle Approval | View | |
| 6 | Prospectus | View | |
| 7 | Board Resolution for Approval of Draft Red Herring Prospectus (DRHP) | View | |
| 8 | Board Resolution for Approval of Red Herring Prospectus (RHP) | View | |
| 9 | Board Resolution for Approval of Prospectus | View | |
| 10 | Consent from Banker to the offer-29-01-2025 | 2024-25 | View |
| 11 | Consent from Book Running Lead Manager-25-09-2024 | 2024-25 | View |
| 12 | Consent from CFO-26-08-2024 | 2024-25 | View |
| 13 | Consent from Compliance Officer & Company Secretary-26-08-2024 | 2024-25 | View |
| 14 | Consent from Directors-26-08-2024 | 2024-25 | View |
| 15 | Consent from RTA-10-09-2024 | 2024-25 | View |
| 16 | Consent from Selling Shareholders-28-08-2024 | 2024-25 | View |
| 17 | Consent Letter from Legal Counsel-20-09-2024 | 2024-25 | View |
| 18 | Consents from Promoters-28-08-2024 | 2024-25 | View |
| # | Title | Year | Action |
|---|---|---|---|
| 1 | Certificate from Statutory Auditor in terms of Regulation 169(5) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“ICDR Regulations)-03-02-2026 | 2025-26 | View |
| 2 | PCS Certificate confirming compliance with Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, for the proposed Preferential Issue of Fully Convertible Equity Warrants | 2025-26 | View |
| 3 | Outcome of Board meeting held 10-10-2025 | 2025-26 | View |
| 4 | Valuation Report on fair value of Equity Shares of Chandan Healthcare Limited as of October 06, 2025 | 2025-26 | View |
| 5 | Outcome of Preferential Issue Committee | 2025-26 | View |
| 6 | Intimation of Board Meeting under Regulation 29 of SEBI (LODR) Regulations, 2015 | 2025-26 | View |
| 7 | In principle Approval NSE-23-01-2026 | 2025-26 | View |
| # | Title | Year | Action |
|---|---|---|---|
| 1 | CDSL TPA-25-09-2024 | 2024-25 | View |
| 2 | Market Making Agreement-31-01-2025 | 2024-25 | View |
| 3 | NSDL-TPA-02-09-2024 | 2024-25 | View |
| 4 | Offer Agreement-28-09-2024 | 2024-25 | View |
| 5 | Public offer Account and Sponsor Bank Agreement-31-01-2025 | 2024-25 | View |
| 6 | RTA Agreement-11-09-2024 | 2024-25 | View |
| 7 | Share Escrow Agreement-31-01-2025 | 2024-25 | View |
| 8 | Syndicate Agreement-31-01-2025 | 2024-25 | View |
| 9 | Underwriting Agreement-31-01-2025 | 2024-25 | View |
| # | Title | Year | Action |
|---|---|---|---|
| 1 | Investor Grievance | View |
Welcome to the Investors page of Chandan Diagnostic, where transparency and accountability are at the forefront of our engagement with investors. As a leading provider of diagnostic services, we understand the importance of fostering trust and providing our investors with the information they need to make informed decisions.
Here, we invite you to connect with us to gain access to relevant details and insights that showcase our financial performance, growth strategies, and vision for the future. Whether you're a current investor, potential shareholder, or financial analyst, we're committed to providing you with the transparency and clarity you seek.
By connecting with us, you'll have the opportunity to engage directly with our investor relations team and gain deeper insights into our business operations, financial metrics, and strategic initiatives. Whether you have questions about our revenue streams, profitability margins, or growth prospects, we're here to provide you with the information and support you need.
Our investor relations team is dedicated to ensuring that you have access to timely and accurate information, enabling you to make informed investment decisions. Whether you prefer to connect via email, phone, or arrange a meeting, we're here to accommodate your needs and provide the information you seek.
Connect with us today to unlock the relevant details and insights you need to evaluate Chandan Diagnostic as an investment opportunity. We welcome the opportunity to engage with you, address your inquiries, and provide the information you need to confidently consider investing in our company.
Thank you for your interest in Chandan Diagnostic. We look forward to connecting with you and building a strong and transparent relationship with our investors.
Corporate Governance at Chandan Diagnostic: Upholding Excellence and Integrity
At Chandan Diagnostic, we hold ourselves to the highest standards of corporate governance, recognizing its fundamental importance in sustaining trust, transparency, and accountability across all facets of our operations. Our commitment to excellence and integrity is evident in every aspect of our corporate governance framework, which serves as the cornerstone of our organizational ethos.
Key Principles of Corporate Governance
- Transparency: We believe in fostering transparency by providing clear, accurate, and timely information to all stakeholders. From financial reporting to strategic initiatives, we strive to maintain open communication channels that promote trust and confidence in our organization.
- Accountability: We uphold accountability by establishing clear lines of responsibility and ensuring that decision-makers are held accountable for their actions. Our governance structure includes checks and balances that promote oversight and accountability at all levels of the organization.
- Integrity: Integrity is the foundation of our corporate governance framework. We adhere to the highest ethical standards in all our interactions, conducting business with honesty, fairness, and integrity. Our commitment to integrity extends to our relationships with customers, employees, suppliers, and the broader community.
- Ethical Leadership: Our leadership team sets the tone for ethical conduct within the organization. We promote a culture of integrity and ethical behavior, encouraging our leaders to lead by example and uphold the highest standards of professionalism and integrity in their decision-making.
- Board Independence: The independence of our board of directors is essential to effective corporate governance. We maintain a diverse and independent board composed of experienced professionals who provide impartial oversight and guidance to ensure the interests of shareholders are protected.
Corporate Governance Practices at Chandan Diagnostic
- Board of Directors: Our board of directors plays a pivotal role in overseeing the strategic direction and performance of the organization. Comprised of experienced professionals from diverse backgrounds, our board provides independent oversight and guidance to management, ensuring alignment with shareholder interests and corporate values.
- Code of Conduct and Ethics: We have implemented a comprehensive Code of Conduct and Ethics that outlines the principles and standards of behavior expected from all employees, directors, and stakeholders. Our Code of Conduct reflects our commitment to integrity, honesty, respect, and ethical conduct in all business activities.
- Risk Management: We maintain robust risk management processes to identify, assess, and mitigate risks that may impact our business operations or financial performance. Our risk management framework includes regular risk assessments, internal controls, and contingency plans to address potential risks effectively.
- Internal Controls: We have established internal control mechanisms to safeguard our assets, ensure compliance with laws and regulations, and maintain the integrity of our financial reporting. Our internal control framework includes policies, procedures, and monitoring mechanisms to promote accountability and transparency.
- Stakeholder Engagement: We value the input and feedback of our stakeholders and actively engage with them to understand their concerns, address their needs, and build trust and confidence in our organization. We maintain open channels of communication with shareholders, employees, customers, suppliers, and the broader community to foster dialogue and collaboration.
At Chandan Diagnostic, corporate governance is not just a regulatory requirement; it is a fundamental aspect of our corporate culture and identity. We are committed to upholding the highest standards of governance, guided by principles of transparency, accountability, integrity, and ethical leadership. Through our governance practices, we aim to build trust, foster sustainability, and create long-term value for all our stakeholders.
